Over the past two years, for instance, he has published studies maintaining the Chantix anti-smoking pill is unsuitable for first-line use (read here and here) and a meta-analysis indicating the mist form of the Spiriva inhaler that is used to treat chronic obstructive pulmonary disease had a 52 percent increase in mortality risk compared with a placebo ( see this).